|
|
Article: Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera.
- Article from:
- Biotech Week
- Article date:
- September 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biovail Corporation (NYSE:BVF) (TSX:BVF) announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera's JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson's Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia (see also Biovail Corporation).
Bill Wells, Biovail's Chief Executive Officer said, "This agreement ...